Information Provided By:
Fly News Breaks for June 20, 2018
BIIB, PTCT, IONS
Jun 20, 2018 | 05:59 EDT
Barclays analyst Gena Wang upgraded PTC Therapeutics (PTCT) to Equal Weight from Underweight while downgrading Ionis Pharmaceuticals (IONS) to Underweight from Equal Weight. The analyst raised her price target on the former to $40 from $26 and lowered her price target on the latter to $45 from $52. Following PTC's new data in spinal muscular atrophy data, the analyst believes its risdiplam has "disruptive potential" to Ionis and Biogen's (BIIB) Spinraza.
News For IONS;PTCT;BIIB From the Last 2 Days
IONS
Mar 28, 2024 | 10:40 EDT
Meetings to be held in Los Angeles on April 2 and in San Francisco on April 3 hosted by Piper Sandler.
PTCT
Mar 28, 2024 | 08:34 EDT
PTC Therapeutics submitted the sepiapterin MAA to the European Medicines Agency, or EMA. The MAA submission is for the treatment of pediatric and adult patients with Phenylketonuria, including the full spectrum of disease subtypes. Phenylketonuria, or PKU, is a rare, inherited metabolic disease, which affects the brain. The sepiapterin MAA includes the results of the phase 3 APHENITY trial in which sepiapterin had a statistically significant and clinically meaningful reduction in blood phenylalanine levels in pediatric and adult PKU patients. PTC expects to submit the sepiapterin NDA to the FDA no later than the third quarter of 2024. Submissions in 2024 are planned in a number of additional key countries where PTC has existing rare disease commercial infrastructure including Brazil and Japan.